TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26034983

Group type: EXPERIMENTAL
Intervention: ESM self‐monitoring combined with weekly PA‐focused feedback sessions
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: ESM self‐monitoring combined with six weekly sessions without feedback
Number of subjects: 102

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 102
Study: 24955642

Group type: EXPERIMENTAL
Intervention: Astaxanthin (2 mg/day) combined with collagen hydrolysate (3 g/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Astaxanthin and collagen hydrolysate
Number of subjects: 44
Study: 22499290

Group type: EXPERIMENTAL
Intervention: Chlortalidone (12.5-25 mg daily)
Number of subjects: 2409

Group type: COMPARATOR
Intervention: Other antihypertensive medications (excluding thiazides)
Number of subjects: 2409
Study: 20634226

Group type: EXPERIMENTAL
Intervention: Telephone-based mutual peer support intervention
Number of subjects: 54
Study: 17620073

Group type: EXPERIMENTAL
Intervention: 3-year subcutaneous specific immunotherapy (SIT) with standardized allergen extracts of grass and/or birch
Number of subjects: 147

Group type: COMPARATOR
Intervention: No specific immunotherapy (Control)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: SIT (3-year course)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: SIT
Number of subjects: 147
Study: 16297693

Group type: EXPERIMENTAL
Intervention: Sevoflurane (2% to 3%)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Halothane (1% to 1.5%)
Number of subjects: 86
Study: 11991793

Group type: EXPERIMENTAL
Intervention: E. purpurea/E. angustifolia (EPA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: E. purpurea/E. angustifolia plus larch arabinogalactan (EPALA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 9836561

Group type: EXPERIMENTAL
Intervention: Testicular androgen ablation (bilateral orchiectomy in 15 and luteinizing hormone‐releasing hormone analogue in 3)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Finasteride (5 mg/day) alone or in combination with flutamide (250 mg three times a day)
Number of subjects: 18
Study: 9094865

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 1918555

Group type: EXPERIMENTAL
Intervention: General coping preparation package (PREP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Relaxation training with guided relaxation imagery (RT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both RT and PREP
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine clinic treatment only
Number of subjects: 60
Study: 6173904

Group type: EXPERIMENTAL
Intervention: Chemotherapy (MOPP + LDB)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Combined treatment (MOPP + LDB + XRT)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 136
Study: 30902420

Group type: EXPERIMENTAL
Intervention: 10 μg (400 IU) vitamin D supplementation
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: 30 μg (1200 IU) vitamin D supplementation
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: High cord blood 25-hydroxyvitamin D (≥100 nmol/L)
Number of subjects: 975
Study: 28374661

Group type: EXPERIMENTAL
Intervention: Mindfulness-based psychoeducation group (MBPEG)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Conventional psychoeducation group (CPEG)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 342
Study: 26503964

Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 24413638

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon β‐1a, 44 μg sc three times weekly or once weekly, for 24 months or until diagnosis of clinically definite multiple sclerosis (CDMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22520631

Group type: EXPERIMENTAL
Intervention: C-reactive protein levels
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 10-factor modified prognostic model based on the TAX327 trial
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: C-reactive protein levels + TAX327 model risk estimates
Number of subjects: 220
Study: 20061231

Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive case management programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypothetical effects of case management
Number of subjects: 0
Study: 17588396

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (15 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 15179653

Group type: EXPERIMENTAL
Intervention: Knee orthosis (KO)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis (AFO)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Knee-ankle-foot orthosis (KAFO)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 18
Study: 11454380

Group type: EXPERIMENTAL
Intervention: 900 mg gemfibrozil daily for 6 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: 200 mg fenofibrate daily for 6 weeks
Number of subjects: 22
Study: 9728307

Group type: EXPERIMENTAL
Intervention: Gamma AP locking nail (GAPN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Compression hip screw (CHS)
Number of subjects: 60
Study: 8700804

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2808867

Group type: EXPERIMENTAL
Intervention: Lidocaine with 20 micrograms epinephrine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lidocaine with 80 micrograms epinephrine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Plain lidocaine solution
Number of subjects: 12
Study: 1208040

Group type: EXPERIMENTAL
Intervention: Glutathione‐bicarbonate‐Ringer's (GBR) solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 0
Study: 30607545

Group type: EXPERIMENTAL
Intervention: Aprepitant, palonosetron, and dexamethasone
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (palonosetron and dexamethasone)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 108
Study: 29212812

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 14837

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 14837

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 14837
Study: 26130623

Group type: EXPERIMENTAL
Intervention: Oral ambroxol (40 mg/kg/day, in four divided doses)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 66
Study: 23261355

Group type: EXPERIMENTAL
Intervention: p16-positive women
Number of subjects: 1042

Group type: COMPARATOR
Intervention: p16-negative women
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: p16 testing
Number of subjects: 1042
Study: 21712501

Group type: EXPERIMENTAL
Intervention: Tailored behavior change program (web-based and individual coaching)
Number of subjects: 314

Group type: COMPARATOR
Intervention: No/low intervention dose
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Medium intervention dose
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: High intervention dose
Number of subjects: 314
Study: 18618371

Group type: EXPERIMENTAL
Intervention: 5 microg ramosetron hydrochloride once daily for 12 weeks
Number of subjects: 539

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study: 16841626

Group type: EXPERIMENTAL
Intervention: Duloxetine (40-120 mg/day)
Number of subjects: 896

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 896

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 896
Study: 12586006

Group type: EXPERIMENTAL
Intervention: Isotope ratio mass spectrometer (IRMS)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nondispersive isotope‐selective infrared spectrometer (NDIRS)
Number of subjects: 41
Study: 10671629

Group type: EXPERIMENTAL
Intervention: Selenate-supplemented formula (28 microg Se/8 oz)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Selenite-supplemented formula (28 microg Se/8 oz)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Non-fortified formula (7 microg Se/8 oz)
Number of subjects: 79
Study: 9068934

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8103648

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: General anesthesia with thiopental (2‐4 mg/kg) and low fentanyl dose (5 micrograms/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: General anesthesia with thiopental (2‐4 mg/kg) and high fentanyl dose (30 micrograms/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Light general anesthetic
Number of subjects: 18

Group type: COMPARATOR
Intervention: Deeper anesthetic
Number of subjects: 18

Group type: COMPARATOR
Intervention: Atrioventricular conduction (PQ-time)
Number of subjects: 18
Study: 3785608

Group type: EXPERIMENTAL
Intervention: Extracranial-intracranial bypass surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best available medical therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 29910611

Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol
Number of subjects: 3041

Group type: COMPARATOR
Intervention: tiotropium
Number of subjects: 3041

Group type: COMPARATOR
Intervention: olodaterol
Number of subjects: 3041
Study: 27580428

Group type: EXPERIMENTAL
Intervention: Endobronchial valves (EBVs) plus standard of care (SoC)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Endobronchial valves (EBVs)
Number of subjects: 93
Study: 24811183

Group type: EXPERIMENTAL
Intervention: Conventional hemodialysis (HD) sessions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hemodialysis with blood volume tracking (HD-BVT)
Number of subjects: 10
Study: 22494879

Group type: COMPARATOR
Intervention: Alcoholic beverage
Number of subjects: 96

Group type: COMPARATOR
Intervention: Nicotinized cigarette
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nicotine and alcohol co-administration
Number of subjects: 96
Study: 20356567

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination in HIV uninfected individuals
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination in HIV infected individuals
Number of subjects: 27

Group type: COMPARATOR
Intervention: Hepatitis B vaccination
Number of subjects: 27
Study: 17681713

Group type: EXPERIMENTAL
Intervention: Duplex ultrasound (DUS) surveillance after carotid stenting and angioplasty (CAS)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: DUS surveillance
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Endovascular or surgical repair for high-grade stenosis
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: DUS surveillance algorithm
Number of subjects: 111
Study: 16234451

Group type: EXPERIMENTAL
Intervention: Pressure topical anaesthesia
Number of subjects: 18

Group type: COMPARATOR
Intervention: Injection anaesthesia
Number of subjects: 18
Study: 12167550

Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Risperidone (0.75 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Methamphetamine (20 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (with methamphetamine)
Number of subjects: 36
Study: 10459902

Group type: EXPERIMENTAL
Intervention: Cationic lipid-mediated CFTR gene transfer (active treatment)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (lipid alone)
Number of subjects: 16
Study: 8582818

Group type: EXPERIMENTAL
Intervention: Angioplasty or bypass grafting procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillators and heart transplantations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General health outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Referral for diagnostic and therapeutic procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research efforts for equitable health care
Number of subjects: 0
Study: 2693373

Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 31759193

Group type: EXPERIMENTAL
Intervention: PQ912 treatment (glutaminylcyclase inhibitor)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 30098272

Group type: EXPERIMENTAL
Intervention: viable cryopreserved placental membrane (vCPM)
Number of subjects: 62

Group type: COMPARATOR
Intervention: human fibroblast-derived dermal substitute (hFDS)
Number of subjects: 62
Study: 28272673

Group type: EXPERIMENTAL
Intervention: LigaSure™
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PlasmaKinetics™
Number of subjects: 18

Group type: COMPARATOR
Intervention: Classic bipolar energy modality
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: EnSeal®
Number of subjects: 18
Study: 25795059

Group type: EXPERIMENTAL
Intervention: Phaco-canaloplasty (PC)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Phaco-non-penetrating deep sclerectomy (PDS)
Number of subjects: 59
Study: 24009318

Group type: EXPERIMENTAL
Intervention: Wafer group (n=45) biting on a soft acrylic wafer during debond
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (n=45)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 20974053

Group type: EXPERIMENTAL
Intervention: Guided imagery intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo control intervention (listening to audio book segments)
Number of subjects: 20
Study: 19784511

Group type: EXPERIMENTAL
Intervention: 4 L.min‐1 of oxygen (Group O)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Medical air (Group S)
Number of subjects: 94
Study: 17035223

Group type: EXPERIMENTAL
Intervention: Self-learning computer module (SLCM) instruction
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional instruction
Number of subjects: 52
Study: 12784383

Group type: EXPERIMENTAL
Intervention: MMP-1 epitope
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: MMP-3 epitope
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control peptides
Number of subjects: 13
Study: 10642349

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8 to 16 mg daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (15 control subjects)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 15
Study: 9306438

Group type: EXPERIMENTAL
Intervention: Naugle exophthalmometer
Number of subjects: 135

Group type: COMPARATOR
Intervention: Hertel exophthalmometer
Number of subjects: 135
Study: 8350845

Group type: EXPERIMENTAL
Intervention: Pressure relief mattress (PRM)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard, firm mattress (Control)
Number of subjects: 128
Study: 3520129

Group type: EXPERIMENTAL
Intervention: Maltitol (50g)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Maltitol (10g 3 times daily for 5 days)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Maltitol
Number of subjects: 50
Study: 31545373

Group type: EXPERIMENTAL
Intervention: Combination therapies in single-arm trials
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination therapies with observed rates 10 percentage points higher than upper targets
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Single-arm combination trials
Number of subjects: 120
Study: 28944500

Group type: EXPERIMENTAL
Intervention: Absurd events with parent laughter
Number of subjects: 113

Group type: COMPARATOR
Intervention: Absurd events with neutral parent affect
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Ordinary events
Number of subjects: 113
Study: 27368085

Group type: EXPERIMENTAL
Intervention: Trauma scripts
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Stress scripts
Number of subjects: 25

Group type: COMPARATOR
Intervention: Neutral scripts
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: All scripts (trauma, stress, neutral)
Number of subjects: 25
Study: 24996596

Group type: EXPERIMENTAL
Intervention: Supported Care, a multimodal smoking cessation intervention
Number of subjects: 800

Group type: COMPARATOR
Intervention: Normal Care, consisting of existing hospital care only
Number of subjects: 800
Study: 22257614

Group type: EXPERIMENTAL
Intervention: Verapamil SR treatment strategy
Number of subjects: 2317

Group type: EXPERIMENTAL
Intervention: Atenolol treatment strategy
Number of subjects: 2317

Group type: COMPARATOR
Intervention: Both treatment strategies
Number of subjects: 2317
Study: 20169490

Group type: EXPERIMENTAL
Intervention: Water suppression system (0.13, 0.06, 0.03, or 0.02 L/sec of water)
Number of subjects: 2000000

Group type: EXPERIMENTAL
Intervention: Local exhaust ventilation (LEV) system (0.24, 0.13, or 0.12 m(3)/sec of dust laden air)
Number of subjects: 2000000

Group type: COMPARATOR
Intervention: No control treatment
Number of subjects: 2000000
Study: 18023335

Group type: EXPERIMENTAL
Intervention: Formoterol (2x9 microg lower dose; 6x9 microg higher dose)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Salbutamol (3x400 microg lower dose; 9x400 microg higher dose)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Formoterol and Salbutamol
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 26
Study: 16569189

Group type: EXPERIMENTAL
Intervention: Evidence-based implementation (EBI)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study: 12757028

Group type: EXPERIMENTAL
Intervention: Ozonated autohemotherapy with ozone concentration 50 microg/ml per gram of blood
Number of subjects: 12

Group type: COMPARATOR
Intervention: Autohemotherapy with blood exposure to oxygen
Number of subjects: 12
Study: 11134094

Group type: EXPERIMENTAL
Intervention: 0.25 mg/day micronized 17ss-estradiol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.5 mg/day micronized 17ss-estradiol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1.0 mg/day micronized 17ss-estradiol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9079233

Group type: EXPERIMENTAL
Intervention: Lisinopril treatment
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Lisinopril/hydrochlorothiazide treatment
Number of subjects: 900

Group type: COMPARATOR
Intervention: Intensified non-pharmacological treatment
Number of subjects: 900

Group type: COMPARATOR
Intervention: Previous or adjusted medication
Number of subjects: 900
Study: 8436163

Group type: EXPERIMENTAL
Intervention: Cicletanine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3717956

Group type: COMPARATOR
Intervention: Regimen A (CDDP 75 mg/m2 and ADM 50 mg/m2 every 4 weeks)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Regimen B (CDDP 75 mg/m2, ADM 50 mg/m2, plus VCR 1.4 mg/m2 on day 1 and 0.7 mg/m2 on day 7 every 4 weeks)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Responders (both regimens)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Non-responders (both regimens)
Number of subjects: 85
Study: 31773475

Group type: EXPERIMENTAL
Intervention: Total bilirubin levels measured at baseline
Number of subjects: 3824

Group type: EXPERIMENTAL
Intervention: Genetically elevated total bilirubin level (rs6742078 variant)
Number of subjects: 3824
Study: 30516797

Group type: EXPERIMENTAL
Intervention: Sertraline plus enhanced medication management
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy plus sertraline
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy plus placebo
Number of subjects: 223
Study: 27779776

Group type: EXPERIMENTAL
Intervention: Sildenafil 10 mg as a bolus followed by 2.5 mg infusion over 2 hours
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sildenafil doses (2.5 mg, 5 mg, 10 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sildenafil (Revatio®)
Number of subjects: 36
Study: 25406308

Group type: EXPERIMENTAL
Intervention: Social media exposure from Circulation (121 articles)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control group (122 articles)
Number of subjects: 243
Study: 23601186

Group type: EXPERIMENTAL
Intervention: Oral paricalcitol, 2 μg per day for the first year posttransplant
Number of subjects: 100

Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral paricalcitol, 2 μg per day
Number of subjects: 100
Study: 21834455

Group type: EXPERIMENTAL
Intervention: Multidisciplinary preschool early intervention program for 8 months
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 81
Study: 19320625

Group type: EXPERIMENTAL
Intervention: B-BAES (Brief Biphasic Alcohol Effects Scale)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: BAES (Biphasic Alcohol Effects Scale)
Number of subjects: 190
Study: 16689086

Group type: EXPERIMENTAL
Intervention: Central neurotropic preparations in addition to routine medicines
Number of subjects: 181

Group type: COMPARATOR
Intervention: Routine preparations only
Number of subjects: 181
Study: 15077084

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 921

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 921
Study: 11808574

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) training at -4.0 kPa for 1 hour per day during the last week of HDT.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 12
Study: 9386016

Group type: EXPERIMENTAL
Intervention: Gentle tactile contact
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vision availability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Touch and vision interaction
Number of subjects: 0
Study: 7969280

Group type: COMPARATOR
Intervention: 0.45% saline
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: saline plus mannitol
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: saline plus furosemide
Number of subjects: 78

Group type: COMPARATOR
Intervention: saline
Number of subjects: 78